Loading news article.

Newsfiscal.ai

Atrium Therapeutics Doses First Patient in Corventis Clinical Trial

Oct 27, 2026, 09:03 ET · Published

Article summary

Atrium Therapeutics has initiated the Phase 1/2 Corventis clinical trial by dosing the first patient with ATR 1072 for the treatment of PRKAG2 syndrome.

An excerpt from the original article.

Related companies

Atrium Therapeutics, Inc. Common StockRNAView stock

Analyzed by WAPE AI.

Preparing English content…

Repost

Comments —

Loading comments…